BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, January 14, 2026
Home » Newsletters » BioWorld

BioWorld

Jan. 23, 2018

View Archived Issues

Muscle CAR? Celgene’s $9B offer for Juno starts pundits weighing traction, final laps

Now that Celgene Corp. has made its $9 billion move to take over Juno Therapeutics Inc., advancing in the ever-hot chimeric antigen receptor (CAR) T-cell space, speculation has turned to the ultimate odds of dominance, eventual sales numbers if the CD19-targeting JCAR-017 wins FDA clearance, and how that new deal fits alongside Celgene’s existing anti-B cell maturation antigen (BCMA) pact with Bluebird Bio Inc. Read More

In the clinic

Nanobiotix SA, of Paris, reported intermediate data from a phase I/II trial testing NBTXR-3, hafnium oxide nanoparticles, in liver cancers, including primary hepatocellular cancer and liver metastasis from other tumors, at the ASCO Gastrointestinal Cancers Symposium in San Francisco. Of the seven evaluable patients, three achieved a complete response and three were partial responders. Read More

Sanofi snags hemophilia player Bioverativ with $11.6B bid

Piper Jaffray analyst Christopher Raymond called Sanofi SA’s takeover of Bioverativ Inc. for $11.6 billion “just what the doctor ordered” and a positive signal for the sector overall. Paris-based Sanofi disclosed early Monday that it will acquire Bioverativ by way of a tender offer expected next month for the Waltham, Mass.-based company’s outstanding shares (NASDAQ:BIVV) at $105 each – a 64 percent premium to Friday’s closing price of $62.75. Read More

Vical, Astellas see CMV vaccine fail in phase III HST study

Shares of San Diego-based Vical Inc. (NASDAQ:VICL) fell 23 percent, or 43 cents, to $1.44 Monday as longtime partner Astellas Pharma Inc. took the wraps off top-line data showing that ASP-0113, a vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in hematopoietic stem cell transplant (HCT) recipients, failed to meet primary or secondary endpoints of the phase III study. Read More

U.S. Senate shutdown compromise could delay full funding for FDA, NIH

After three days of a partial shutdown, it looks like it’s back to business as usual for the U.S. government – sort of. Read More

South Korean government to ease restrictions for gene therapies, organ donations

HONG KONG – South Korean authorities are expected to ease restrictions for the country’s biotech industry, especially for regulations surrounding gene therapies and organ donation. Read More

Financings

Eureka Therapeutics Inc., of Emeryville, Calif., disclosed the successful completion of a $60 million series D financing round. Read More

Other news to note

Klogene Therapeutics Inc., of Boston, and Boston University School of Medicine said a paper published in the Journal of Molecular Neuroscience showed efficient transcriptional activation of the anti-aging multifunctional gene Klotho by CRISPR/Cas9. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 13, 2026.
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Lung cancer illustration

    LINC01116 has prognostic value in lung cancer, study shows

    BioWorld MedTech
    Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing